Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer

Osimertinib is a third‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that has shown marked antitumor activity in patients with EGFR‐mutated non–small‐cell lung cancer (NSCLC). However, these effects are transient and most patients develop resistance. Reversible d...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hirofumi, Sakakibara‐Konishi, Jun, Furuta, Megumi, Shoji, Tetsuaki, Tsuji, Kosuke, Morinaga, Daisuke, Kikuchi, Eiki, Kikuchi, Junko, Noguchi, Takuro, Hatanaka, Kanako C., Hatanaka, Yutaka, Shinagawa, Naofumi, Konno, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067397/
https://www.ncbi.nlm.nih.gov/pubmed/36411521
http://dx.doi.org/10.1111/cas.15674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067397/
https://www.ncbi.nlm.nih.gov/pubmed/36411521
http://dx.doi.org/10.1111/cas.15674

Ejemplares similares